Pemtumomab Biosimilar – Anti-MUC-1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1997; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Pemtumomab Biosimilar, also known as Anti-MUC-1 mAb, is a monoclonal antibody that targets the MUC-1 antigen. This biosimilar is currently being researched for its potential therapeutic applications in various types of cancer. In this article, we will discuss the structure, activity, and potential applications of Pemtumomab Biosimilar.
Pemtumomab Biosimilar is a recombinant humanized monoclonal antibody that is produced using recombinant DNA technology. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure with two antigen-binding sites, allowing it to bind to two MUC-1 antigens simultaneously.
The primary activity of Pemtumomab Biosimilar is its ability to bind to the MUC-1 antigen. MUC-1 is a glycoprotein that is overexpressed in many types of cancer, including breast, lung, and pancreatic cancer. The overexpression of MUC-1 is associated with tumor growth, invasion, and metastasis, making it an attractive therapeutic target.
By binding to the MUC-1 antigen, Pemtumomab Biosimilar can inhibit the growth and spread of cancer cells. It does this by blocking the interaction between MUC-1 and other proteins that are involved in cancer progression. Additionally, Pemtumomab Biosimilar can also activate the immune system to target and destroy cancer cells, a process known as antibody-dependent cell-mediated cytotoxicity (ADCC).
Pemtumomab Biosimilar is being researched for its potential therapeutic applications in various types of cancer. Some of the specific applications being explored include:
1. Breast Cancer: Studies have shown that MUC-1 is overexpressed in up to 90% of breast cancer cases. Pemtumomab Biosimilar has shown promising results in preclinical studies as a potential treatment for breast cancer. It has been shown to inhibit tumor growth and induce cancer cell death in breast cancer models.
cancer (NSCLC), the most common type of lung cancer. Pemtumomab Biosimilar has been shown to bind to MUC-1 and inhibit the growth and spread of NSCLC cells. It has also been shown to enhance the effectiveness of chemotherapy in lung cancer models.
cancer is one of the most aggressive and deadly forms of cancer, with a very low survival rate. MUC-1 is overexpressed in pancreatic cancer and is associated with poor prognosis. Pemtumomab Biosimilar has shown promising results in preclinical studies as a potential treatment for pancreatic cancer. It has been shown to inhibit tumor growth and enhance the effectiveness of chemotherapy.
4. Other Cancers: In addition to breast, lung, and pancreatic cancer, Pemtumomab Biosimilar is also being researched for its potential applications in other types of cancer, including ovarian, colon, and prostate cancer. These cancers also overexpress MUC-1, making it a potential therapeutic target for Pemtumomab Biosimilar.
Pemtumomab Biosimilar, also known as Anti-MUC-1 mAb, is a promising monoclonal antibody that targets the MUC-1 antigen. Its structure, activity, and potential applications make it a promising candidate for the treatment of various types of cancer. Further research and clinical trials are needed to fully understand the potential of Pemtumomab Biosimilar as a therapeutic option for cancer patients.
ProteoGenix catalogue number PX-TA1997. For research use only.
Target: Pemtumomab Biosimilar – Anti-MUC-1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >90% by SDS-PAGE.; Buffer: 0.01M PBS, pH 7.4.; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Pemtumomab Biosimilar – Anti-MUC-1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
